Gerard Boghossian
Podiatrist · Lancaster, CANPI 1942263322
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $19,248 of the $26,837 with a category attached, or 71.7%. Smith+Nephew accounts for 85.9% of it on its own, with 20 other manufacturers making up the rest. Reporting peaked in 2021 at $7,764 and has fallen 92.3% since, to $595 in 2025. Among podiatrist clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 214 payments — averaging $125.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Smith+Nephew$23K
- Paragon 28, Inc.$1K
- Paratek Pharmaceuticals, Inc.$1K
- Urgo Medical North America, LLC$246
- Organogenesis Inc.$238
- Amgen$193
- plus $730 from 15 others
Across 82 payments — averaging $2556.59 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Biotissue Holdings Inc.$210K
What the payments were for
- Speaking & faculty fees$19,24872%
- Travel & lodging$2,95811%
- Food & beverage$4,63217%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Smith+Nephew | 94 | $23,046 |
| Paragon 28, Inc. | 8 | $1,359 |
| Paratek Pharmaceuticals, Inc. | 76 | $1,026 |
| Urgo Medical North America, LLC | 1 | $246 |
| Organogenesis Inc. | 2 | $238 |
| Amgen | 10 | $193 |
| Johnson & Johnson | 4 | $159 |
| Treace Medical Concepts, Inc. | 4 | $120 |
| Solventum Corporation | 1 | $107 |
| Bioventus LLC | 2 | $66 |
| Next Science LLC | 1 | $38 |
| Integra Lifesciences Corporation | 1 | $36 |
| KCI USA, Inc. | 1 | $35 |
| Gilead | 1 | $32 |
| Forte Bio-pharma LLC | 2 | $25 |
| SPR Therapeutics, Inc | 1 | $23 |
| Biotissue Holdings Inc. | 1 | $22 |
| Nabriva Therapeutics, PLC | 1 | $19 |
| Advanced Oxygen Therapy Inc. | 1 | $19 |
| GSK | 1 | $16 |
| Melinta Therapeutics, LLC | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Santyl$11,334
- COLLAGENASE SANTYL$9,853
- REGRANEX$5,854
- Oasis$5,704
- Portfolio$905
- APEX 3D$347
- UrgoK2$246
- VASHE WOUND SOLUTION 250 ML (8.5 FL OZ) FLIP TOP CAP$246
- Puraply Antimicrobial$125
- Apligraf$113
- BME NITINOL CONTINUOUS COMPRESSION IMPLANTS$111
- ACTIV.A.C.$107
- V.A.C. INSTILL$107
- PREVENA$107
How this compares
$26,837 in reported general payments places this provider in the 95th percentile of 721 podiatrist providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| NuzyraOmadacycline Tosylate | 19 | $132,076 |
| SantylCollagenase Clostridium Hist. | 151 | $106,818 |
| Ciclopirox | 86 | $1,730 |
| Doxycycline Hyclate | 112 | $974 |
| CiclopiroxCiclopirox Olamine | 31 | $917 |
| Diclofenac Sodium | 14 | $557 |
| Doxycycline Monohydrate | 26 | $352 |
| Triamcinolone Acetonide | 60 | $348 |
| Ammonium Lactate | 35 | $233 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 23 | $167 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 14 | $130 |
| Methylprednisolone | 12 | $64 |
| Ciprofloxacin Hcl | 11 | $45 |
| Levofloxacin | 13 | $32 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Paratek Pharmaceuticals, Inc.Nuzyra | $1,026 | $132,07619 claims |
| Smith+NephewSantyl | $23,046 | $106,818151 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 721 podiatrist providers in California.
Other podiatrist in Lancaster
- Shannon RushPleasanton$1.9M
- Babak BaravarianSanta Monica$1.1M
- Robert KleimanCalexico$913K
- Bruce LawrenceOceanside$810K
- David ArmstrongLos Angeles$695K
- Philip WrotslavskyPoway$269K
- Travis WestermeyerEncinitas$158K
- Adrienne EstesPomona$129K
- Ronald LiebermanEncinitas$109K
- Matthew DoyleMountain View$92K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.